Struggling With Great Stock Picks? Discover StockInvest.us Top Gems!

Range Low Price High Price Comment
30 days $38.60 $44.37 Friday, 10th May 2024 XENE stock ended at $40.54. This is 4.59% less than the trading day before Thursday, 9th May 2024. During the day the stock fluctuated 10.26% from a day low at $38.60 to a day high of $42.56.
90 days $38.60 $50.99
52 weeks $27.99 $50.99

Historical Xenon Pharmaceuticals Inc. prices

Date Open High Low Close Volume
Feb 29, 2024 $47.83 $48.41 $46.54 $47.20 645 225
Feb 28, 2024 $49.25 $49.70 $47.64 $47.84 524 533
Feb 27, 2024 $49.60 $49.88 $48.65 $49.63 467 564
Feb 26, 2024 $49.26 $50.59 $48.21 $49.13 333 047
Feb 23, 2024 $49.21 $49.51 $48.74 $49.46 188 451
Feb 22, 2024 $48.83 $50.59 $48.83 $49.25 727 809
Feb 21, 2024 $48.35 $49.08 $47.85 $48.83 272 268
Feb 20, 2024 $48.91 $49.23 $47.95 $48.42 206 023
Feb 16, 2024 $48.44 $49.05 $48.26 $48.91 201 060
Feb 15, 2024 $48.71 $49.00 $48.11 $48.69 219 881
Feb 14, 2024 $48.56 $49.01 $48.17 $48.50 234 087
Feb 13, 2024 $47.75 $49.44 $47.00 $48.06 520 005
Feb 12, 2024 $49.96 $50.98 $48.99 $49.36 575 165
Feb 09, 2024 $48.46 $50.08 $48.21 $50.04 496 613
Feb 08, 2024 $47.38 $48.30 $46.93 $48.18 248 607
Feb 07, 2024 $47.73 $47.96 $46.67 $47.13 376 877
Feb 06, 2024 $46.31 $47.91 $46.11 $47.68 279 904
Feb 05, 2024 $45.91 $46.59 $44.63 $46.39 314 255
Feb 02, 2024 $45.80 $45.99 $44.92 $45.92 221 539
Feb 01, 2024 $45.43 $47.03 $44.97 $46.43 243 295
Jan 31, 2024 $45.75 $46.46 $45.22 $45.22 221 136
Jan 30, 2024 $46.19 $46.78 $45.38 $45.67 297 704
Jan 29, 2024 $45.61 $47.17 $45.30 $46.50 465 193
Jan 26, 2024 $45.11 $45.73 $44.93 $45.64 335 766
Jan 25, 2024 $44.10 $45.19 $43.75 $45.15 213 567
Click to get the best stock tips daily for free!

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals. Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment o... XENE Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT